32.29
-0.39(-1.19%)
Currency In USD
| Previous Close | 32.68 |
| Open | 32.13 |
| Day High | 32.49 |
| Day Low | 31.89 |
| 52-Week High | 73.8 |
| 52-Week Low | 24.34 |
| Volume | 502,690 |
| Average Volume | 3.38M |
| Market Cap | 4.02B |
| PE | -15.91 |
| EPS | -2.03 |
| Moving Average 50 Days | 30.6 |
| Moving Average 200 Days | 38.55 |
| Change | -0.39 |
If you invested $1000 in Apellis Pharmaceuticals, Inc. (APLS) since IPO date, it would be worth $2,301.5 as of December 30, 2024 at a share price of $32.29. Whereas If you bought $1000 worth of Apellis Pharmaceuticals, Inc. (APLS) shares 5 years ago, it would be worth $1,094.21 as of December 30, 2024 at a share price of $32.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 27, 2024 12:00 PM GMT
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences: Evercore ISI HealthCONx Conference: Fireside chat on W
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
GlobeNewswire Inc.
Nov 12, 2024 12:00 PM GMT
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT.
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 05, 2024 12:05 PM GMT
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million Increase in demand offset by hi